Saturday, October 14, 2023 - Agenda

Objective #1: Learn what a biologic medication is

Objective #2: Know the difference between a biologic medication, biosimilar medication, and interchangeable biosimilar medication

Objective #3: Know the types of side effects which can occur with biologic and biosimilar medications

Howard L. Feinberg, DO, MACOI, Associate Dean, Clinical Education Proposed Maryland College of Osteopathic Medicine at Morgan State

Objective #1: Review the current state initiatives of Medical Marijuana Legalization (MML) and Recreational Marijuana Legalization and its economic impact in the US

Objective #2: Assess the current Evidence-based Research of Cannabinoid compounds

Objective #3: Discuss Cannabis Use Disorder as an "underappreciated risk of using cannabis"

C. Clark Milton, DO, FACOI, Assistant Professor of Internal Medicine, West Virginia School of Osteopathic Medicine

Objective #1: Define palliative care in the context of cancer, citing the World Health Organization's official definition.

Objective #2: Discuss the importance of early integration of palliative care in patients with advanced cancer diagnoses

Objective #3: Examine the guidelines and recommendations for integrating palliative care into standard oncology care, as presented by the American Society of Clinical Oncology and the National Comprehensive Cancer Network.

Jason R. Beckrow, DO, FACOI, FAAHPM, HMDC (he/him/his), Assistant Professor, Michigan State University

1. Discuss 2 skills in building a foundation of trust with patients by increasing our listening skills.

2. Identify 2 risk factors in preventing a crisis through whole patient centered care.

3. Identify 3 tools that aid in care giver support.

Sandra P. Gomez, MD, Sage Health Medical Director Provider Training and Care Model Innovation

Objective #1: To understand what the responsibilities physician have with regard to their colleagues being impaired.

Objective #2: Lay out generally accepted practice in the approach to suspected impairment of physicians in the clinical setting.

Objective #3: Clearly delineate the rights of the physician suspected of impairment and the process of aiding them into recovery.

Thomas F. Jan, DO, Founding and Current Chair American Osteopathic Pain Medicine Conjoint Examination Committee

Session details coming soon.

Dominic F. Glorioso, Jr., DO, PhD, FACOI, FAAHPM, HMD (he/him/his), Associate Medical Director, Amedisys Hospice

Thomas F. Jan, DO, Founding and Current Chair American Osteopathic Pain Medicine Conjoint Examination Committee

Objective #1: Discuss criteria for the diagnosis and staging of Chronic Kidney Disease (CKD) and Examine real-world practices for CKD screening and monitoring.

Objective #2: Review the current recommendations for the assessment of kidney function.

Objective #3: Describe methods for prognostication in both early and advanced CKD.

Tarra Faulk, DO, Assistant Professor of Medicine Uniformed Services University of the Health Sciences F. Edward Hébert School of Medicine Bethesda, Maryland

Objective #1: Understand the mechanism of action of thiazide diuretics

Objective #2: Determine if there is sufficient evidence supporting the continued use of thiazide diuretics for reducing risk of calcium oxalate stone formation

Objective #3: Appreciate the current clinical scenarios where use of thiazide diuretics should be considered

David S. Levy, DO, FACOI, FASN (he/him/his), Assistant Professor of Clinical Medicine, University of Rochester School of Medicine

Session details coming soon.

Objective #1: Highlight when to raise awareness for that a glomerular disease may be present

Objective #2: Discuss the epidemiology, prognostic factors and pathogenesis of IgA Nephropathy

Objective #3: Review treatment recommendations for IgA Nephrology given contemporary findings

Laura S. Maursetter, DO, Associate Professor of Nephrology

Objective #1: To understand the Treatment as Prevention

Objective #2: To understand Post-Exposure Prophylaxis

Objective #3: To Understand Pre-Exposure Prophylaxis

Erik D. Wert, DO, FACOI